Ranitidine Hydrochloride - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Modal Labs has secured $750 million in Series D funding at a $15.75 billion valuation, marking a nearly 239% valuation surge in five months as demand for AI inference, GPU cloud infrastructure and autonomous coding agents accelerates, pushing the company's annualized run rate beyond $1 billion. Representative image.

Modal valuation jumps 239% as AI infrastructure demand drives $750m Series D

Salad and Go is coming back after bankruptcy, but competitors bought most of its old drive-thru network

Patient volumes rose 10% at Montrose Regional Health, so why are 77 positions disappearing?

Royal Mail wants 2,500 fewer support roles. Can it afford a frontline retention problem too?

Read More

Pharma Industry News

Solara Active Pharma gets CEP of Ranitidine API restored by EDQM

Solara Active Pharma Sciences said that its certificates of suitability (CEP) for Ranitidine Hydrochloride drug substance (CEP 2001-228)…

July 5, 2021

web analytics